Rock Ventures Iii, L.P.Thir... Net Worth

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Rock Thir RLAY stock SEC Form 4 insiders trading

Rock has made over 1 trades of the Relay Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently Rock sold 5,622,394 units of RLAY stock worth $227,144,718 on 12 January 2021.

The largest trade Rock's ever made was selling 5,622,394 units of Relay Therapeutics stock on 12 January 2021 worth over $227,144,718. On average, Rock trades about 5,622,394 units every 0 days since 2021.

You can see the complete history of Rock Thir stock trades at the bottom of the page.

Insiders trading at Relay Therapeutics

Over the last 4 years, insiders at Relay Therapeutics have traded over $234,228,237 worth of Relay Therapeutics stock and bought 110,000 units worth $2,200,000 . The most active insiders traders include Rock Ventures Iii, L.P.Thir..., Sanjiv Patel, and Donald A Bergstrom. On average, Relay Therapeutics executives and independent directors trade stock every 11 days with the average trade being worth of $406,570. The most recent stock trade was executed by Thomas Catinazzo on 29 July 2024, trading 10,780 units of RLAY stock currently worth $92,277.

What does Relay Therapeutics do?

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Complete history of Rock Thir stock trades at Relay Therapeutics

Relay Therapeutics executives and stock owners

Relay Therapeutics executives and other stock owners filed with the SEC include:

• Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS,
  CEO, Pres & Director
• Dr. Sanjiv K. Patel MBBS, M.A., M.D., M.B.A.,
  CEO, Pres & Director
• Dr. Donald A. Bergstrom M.D., Ph.D.,
  Exec. VP and Head of R&D
• Brian R. Adams J.D.,
  Gen. Counsel & Sec.
• Dr. Mark Murcko Ph.D.,
  Co-Founder & Director
• Alexis A. Borisy A.M.,
  Co-Founder & Independent Chairman
• Jim Watters Ph.D.,
  Sr. VP & Head of Late Research
• Andy Porter,
  Exec. VP & Chief People Officer
• Dr. Deborah Palestrant Ph.D.,
  VP of Corp. Devel. & Strategy
• Peter Rahmer,
  Sr. VP of Corp. Affairs & Investor Relations
• Thomas Catinazzo,
  Sr. VP of Fin.
• Mark Murcko,
  
• Alexis Borisy,
  
• Sekar Kathiresan,
  
• Linda A Hill,
  
• Douglas S Ingram,
  
• Brian Adams,
  Chief Legal Officer
• Donald A Bergstrom,
  President, R&D
• Llcshaw David E Picularium,,
  
• Jami Rubin,
  
• Sanjiv Patel,
  President and CEO
• Pauling (Cayman) Ltd Softba...,
  
• Rock Ventures Iii, L.P.Thir...,
  
• Rock Ventures Iii, L.P.Thir...,
  
• Andy Porter,
  Chief Administrative Officer
• Thomas Catinazzo,
  Chief Financial Officer
• Peter Rahmer,
  See remarks
• Laura Shawver,